From Yahoo Finance: 2025-05-25 16:00:00

Bank of America raised its price target for Merus (MRUS) to $92 from $70, maintaining a Buy rating following positive Phase 2 trial results for petosemtamab and pembrolizumab in treating HNSCC. The trial achieved a 79% 12-month survival rate, surpassing historical benchmarks and positioning the combination as a top treatment option. The interim data showed a 63% overall response rate among patients.

Merus (MRUS) is a Netherlands-based clinical-stage immuno-oncology company specializing in antibody therapeutics development. Bank of America views the promising Phase 2 trial results as positioning the peto + pembr combination as a potentially best-in-class treatment option for patients with HNSCC.

Bank of America’s decision to raise Merus’ (MRUS) price target to $92 from $70 and maintain a Buy rating follows highly favorable Phase 2 trial results for the combination of petosemtamab and pembrolizumab in treating first-line head and neck squamous cell carcinoma. The trial achieved a 12-month objective survival rate of 79% in its full cohort, exceeding historical benchmarks for pembrolizumab monotherapy.



Read more at Yahoo Finance: BofA Maintains Buy Rating on Merus (MRUS), Lifts PT